Because we showed a decrease in the migration capacity of glioblastoma cells under treatment with miR‐218 in our studies, we could conclude then that these changes might be the result of the impact of miR‐218 on CDC42, STAT3, EGF and CTTN. The gene discussed is STAT3; the disease is glioblastoma.